Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04755543Phase 1Unknown

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Role: lead

NCT04756934Phase 1Unknown

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Role: lead

NCT04740021Phase 2Unknown

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Role: lead

NCT04600947Phase 2Unknown

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Role: lead

All 4 trials loaded